Valeant Pharmaceuticals International’s (VRX) Underweight Rating Reaffirmed at Piper Jaffray Companies

Piper Jaffray Companies restated their underweight rating on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a research note published on Friday, July 14th. Piper Jaffray Companies currently has a $10.00 price objective on the specialty pharmaceutical company’s stock.

A number of other analysts have also recently commented on VRX. Jefferies Group LLC set a $18.00 price target on shares of Valeant Pharmaceuticals International and gave the company a buy rating in a research report on Saturday, May 6th. Guggenheim began coverage on shares of Valeant Pharmaceuticals International in a research report on Saturday, June 17th. They set a buy rating and a $18.00 price objective on the stock. Wells Fargo & Company reissued an underperform rating on shares of Valeant Pharmaceuticals International in a research report on Monday, June 12th. HC Wainwright set a $17.00 price objective on shares of Valeant Pharmaceuticals International and gave the stock a hold rating in a research report on Wednesday, May 10th. Finally, Royal Bank Of Canada reissued a market perform rating and set a $19.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Tuesday, June 13th. Four research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $16.96.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded up 1.76% during mid-day trading on Friday, reaching $15.64. The company had a trading volume of 48,544,539 shares. The firm’s market capitalization is $5.44 billion. The stock has a 50 day moving average of $16.44 and a 200-day moving average of $13.39. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $32.74.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 EPS for the quarter, beating the Zacks’ consensus estimate of $0.87 by $1.93. The business had revenue of $2.11 billion for the quarter, compared to analysts’ expectations of $2.17 billion. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. The business’s quarterly revenue was down 11.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.08) earnings per share. Equities analysts predict that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

WARNING: “Valeant Pharmaceuticals International’s (VRX) Underweight Rating Reaffirmed at Piper Jaffray Companies” was posted by BBNS and is the property of of BBNS. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://baseballnewssource.com/markets/valeant-pharmaceuticals-internationals-vrx-underweight-rating-reiterated-at-piper-jaffray-companies-updated-updated-updated/1195933.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 20,000 shares of the business’s stock in a transaction that occurred on Thursday, May 11th. The stock was bought at an average cost of $13.90 per share, with a total value of $278,000.00. Following the acquisition, the director now owns 70,572 shares in the company, valued at $980,950.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.87% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Comerica Bank increased its position in shares of Valeant Pharmaceuticals International by 15.2% in the fourth quarter. Comerica Bank now owns 20,145 shares of the specialty pharmaceutical company’s stock valued at $309,000 after buying an additional 2,655 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Valeant Pharmaceuticals International by 86.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 576,634 shares of the specialty pharmaceutical company’s stock valued at $8,372,000 after buying an additional 268,116 shares during the last quarter. Credit Agricole S A increased its position in shares of Valeant Pharmaceuticals International by 27.4% in the fourth quarter. Credit Agricole S A now owns 56,822 shares of the specialty pharmaceutical company’s stock valued at $825,000 after buying an additional 12,236 shares during the last quarter. GSA Capital Partners LLP increased its position in shares of Valeant Pharmaceuticals International by 32.7% in the fourth quarter. GSA Capital Partners LLP now owns 35,415 shares of the specialty pharmaceutical company’s stock valued at $514,000 after buying an additional 8,718 shares during the last quarter. Finally, Guggenheim Capital LLC increased its position in shares of Valeant Pharmaceuticals International by 18.6% in the fourth quarter. Guggenheim Capital LLC now owns 17,540 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 2,752 shares during the last quarter. 51.14% of the stock is owned by hedge funds and other institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury


Leave a Reply

 
© 2006-2017 BBNS.